CytoDyn Inc. (CYDY)

CytoDyn Income Statement

Financials in millions USD. Fiscal year is June - May.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 31, 2025	May 31, 2024	May 31, 2023	May 31, 2022	May 31, 2021
Revenue	-	-	-	0.27	-
Cost of Revenue	-	-	20.63	73.54	5.03
Gross Profit	-	-	-20.63	-73.28	-5.03
Selling, General & Admin	7.26	10.79	17.14	44.3	34.32
Research & Development	-16.92	7.24	2.63	27.04	53.4
Operating Expenses	-9.66	18.06	19.94	72.13	89.52
Operating Income	9.66	-18.06	-40.58	-145.4	-94.55
Interest Expense	-4.86	-8.67	-15.51	-24.18	-22.11
Interest & Investment Income	0.57	-	-	-	-
Other Non Operating Income (Expenses)	-2.03	-3.06	-18.43	-	-
EBT Excluding Unusual Items	3.34	-29.79	-74.51	-169.59	-116.66
Asset Writedown	-	-	-	-	-10.05
Legal Settlements	-	-	-	-3.85	-10.63
Other Unusual Items	0.41	-20.05	-5.31	-37.38	-39.13
Pretax Income	3.75	-49.84	-79.82	-210.82	-176.47
Net Income	3.75	-49.84	-79.82	-210.82	-176.47
Preferred Dividends & Other Adjustments	-	1.48	6.91	1.63	1.69
Net Income to Common	3.75	-51.32	-86.74	-212.45	-178.15
Shares Outstanding (Basic)	1,206	970	837	677	588
Shares Outstanding (Diluted)	1,243	970	837	677	588
Shares Change (YoY)	28.20%	15.90%	23.58%	15.20%	39.54%
EPS (Basic)	0.00	-0.05	-0.10	-0.31	-0.30
EPS (Diluted)	0.00	-0.05	-0.10	-0.31	-0.30
Free Cash Flow	-8.77	-10.98	-25.11	-77.72	-117.7
Free Cash Flow Per Share	-0.01	-0.01	-0.03	-0.12	-0.20
Operating Margin	-	-	-	-54663.16%	-
Profit Margin	-	-	-	-79867.67%	-
Free Cash Flow Margin	-	-	-	-29219.17%	-
EBITDA	9.68	-18.03	-40.4	-144.62	-92.75
D&A For EBITDA	0.02	0.03	0.18	0.78	1.8
EBIT	9.66	-18.06	-40.58	-145.4	-94.55

Updated Jan 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.